
Mergers ·
ENDRA amends merger agreement with ASP Isotopes and Renergen
The October 1, 2026 amendment sets a $3,800,002.59 minimum cash condition, drops the classified board requirement, and lets Renergen borrow up to $120 million from ASP Isotopes.
NDRA ENDRA Life Sciences Inc.

Mergers ·
The October 1, 2026 amendment sets a $3,800,002.59 minimum cash condition, drops the classified board requirement, and lets Renergen borrow up to $120 million from ASP Isotopes.
ENDRA reported net income of approximately $160,000 for the second quarter of 2026 and said it expects the Noble Africa merger to close in the fourth quarter of 2026.
Nasdaq told ENDRA on July 8, 2026 that it regained compliance with the $2,500,000 minimum stockholders' equity requirement, but the company will be under a one-year panel monitor.
ENDRA agreed on May 27, 2026 to sell 578,387 shares or prefunded warrants, with common warrants for up to 1,156,774 shares, through sole placement agent Lucid Capital Markets, LLC.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $1.8 million | $3.2 million |
| Net income (loss) | -$7.0 million | -$11.5 million |
| Cash from operations | -$5.2 million | -$7.4 million |
| Cash and equivalents | $762,365 | $3.2 million |
Our latest story on this, dated May 28, 2026: "ENDRA expects $3.8 million from private placement of stock and warrants". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 1, 2026: "ENDRA amends merger agreement with ASP Isotopes and Renergen". The story links the filing or release it is based on. Read the story.
ENDRA Life Sciences Inc. trades under the ticker NDRA on NASDAQ.
ENDRA Life Sciences Inc. is listed on NASDAQ.
Our directory records ENDRA Life Sciences Inc. under United States.
aibio.space lists ENDRA Life Sciences Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
ENDRA Life Sciences Inc. reported a net loss of $7.0 million for the fiscal year ended Dec 31, 2025, and used $5.2 million of cash in operations, per its annual report to the SEC.
$1.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$1.7 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on ENDRA Life Sciences, dated Oct 1, 2026: "ENDRA amends merger agreement with ASP Isotopes and Renergen". The October 1, 2026 amendment sets a $3,800,002.59 minimum cash condition, drops the classified board requirement, and lets Renergen borrow up to $120 million from ASP Isotopes. Source.
Our latest listing story, dated Jul 9, 2026: "ENDRA regains Nasdaq stockholders' equity compliance". Nasdaq told ENDRA on July 8, 2026 that it regained compliance with the $2,500,000 minimum stockholders' equity requirement, but the company will be under a one-year panel monitor. Source.
Press Follow on this page to add ENDRA Life Sciences to your Following list, or subscribe to the aibio.space newsletter. We have published 4 stories naming ENDRA Life Sciences so far, in Financings, Listings, Mergers.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction